Loading…
Ryan White Patient Equity and Choice Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
45pct
7d open
vs 5,821 other HR bills in the 113th — cohort avg 49d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2014 · fourth_quarter · Health Issues
H.R. 1074 - National Diabetes Clinical Care Commission Act H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act H.R. 3230 - Veterans' Access to Care through Choice, Accountability, and Transparency Act H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP H.R. 4847 - End Neglected Tropical Diseases Act S. 539 - National Diabetes Clinical Care Commission Act S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine S. 1417 - Newborn Screening Saves Lives Reauthorization Act S. 2917 - Adding Ebola to the FDA Priority Review Voucher Program Act No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned - 21st Century Cures Initiative and related policy issues No bill # assigned - FDA special medical use; issues related to limited population antibacterial drug approval pathway No bill # assigned - FDA accelerated approval policy issues No bill # assigned - Comparative effectiveness policy issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Pharmaceutical supply chain security issues No bill # assigned - 340B policy issues No bill # assigned - Implementation issues relating to the Physician Payment Sunshine Act No bill # assigned - Support for COPD national action plan No bill # assigned - FDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assigned - FDA proposed rule regarding Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Products
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: $580,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2014 · fourth_quarter · Health Issues
H.R. 4260, Ryan White Patient Equity and Choice Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Health Issues
Health LegislationH.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP H.R. 4847 - End Neglected Tropical Diseases Act S. 539 - National Diabetes Clinical Care Commission Act S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine S. 1417 - Newborn Screening Saves Lives Reauthorization Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · third_quarter · Budget/Appropriations
HR 4260 "Commerce, Justice, State FY15 Appropriations" - sections pertaining to NSF; TAA for Firms; University Centers; Economic Development Administration; National Sea Grant; National Space Grant HJ Res 124 "Continuing Appropriations for FY 15" - sections pertaining to research and student financial aid NIH research funding SBE research funding Funding for Title IV Centers of Excellence in CHIP
Client expense: $70,000 · Firm income: Not reported
Government targets: Economic Development Administration, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2014 · third_quarter · Health Issues
H.R. 1074- National Diabetes Clinical Care Commission Act H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act H.R. 3230 - Veterans' Access to Care through Choice, Accountability, and Transparency Act H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP H.R. 4847 - End Neglected Tropical Diseases Act S. 539 - National Diabetes Clinical Care Commission Act S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine S. 1417 - Newborn Screening Saves Lives Reauthorization Act No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned - 21st Century Cures Initiative and related policy issues No bill # assigned - FDA special medical use; issues related to limited population antibacterial drug approval pathway No bill # assigned - FDA accelerated approval policy issues No bill # assigned - Comparative effectiveness policy issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Pharmaceutical supply chain security issues No bill # assigned - 340B policy issues No bill # assigned - Implementation issues relating to the Physician Payment Sunshine Act No bill # assigned - Support for COPD national action plan No bill # assigned - FDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA No bill # assigned - FDA proposed rule regarding electronic distribution of cContent of Labeling for Human Prescription Drug and Biological products
Client expense: $1,140,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
2014 · third_quarter · Health Issues
H.R. 4260, Ryan White Patient Equity and Choice Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2014 · second_quarter · Health Issues
H.R. 1074 - National Diabetes Clinical Care Commission Act H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts H.R. 3204 - Drug Quality and Security Act; provisions relating to pharmacy compounding and supply chain H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP H.R. 4847 - End Neglected Tropical Diseases Act S. 539 - National Diabetes Clinical Care Commission Act S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts S. 957 - Drug Supply Chain Security Act; provisions related to supply chain security S. 959 - Pharmaceutical Compounding Quality and Accountability Act; provisions related to pharmaceutical compounding S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking No bill # assigned - FDA special medical use; issues related to limited population antibacterial drug approval pathway No bill # assigned - FDA accelerated approval policy issues No bill # assigned - Comparative effectiveness policy issues No bill # assigned - Biopharmaceutical innovation policy issues No bill # assigned - Pharmaceutical supply chain security issues No bill # assigned - 340B policy issues No bill # assigned - Implementation issues relating to the Physician Payment Sunshine Act
2014 · second_quarter · Budget/Appropriations
Issues relating to NSF political science funding and NIH social science research HR 4260 "Commerce Justice, State FY 15 Appropriations" - sections pertaining to NSF; TAA for Firms; University Centers; Economic Development Administration; National Sea Grant; National Space Grant no bill numbers - FY 15 appropriations for Department of Defense pertaining to basic and applied research; Labor/HHS/Education pertaining to HHS- Public Health Service, Title VII & VIII programs, NIOSH, NIH, NINR, Medicare/Medicaid; Dept. of Ed - student financial aid programs, international education programs, and graduate education programs; Energy & Water - DOE Office of Science
Client expense: $70,000 · Firm income: Not reported
Government targets: Education, Dept of, Federal Retirement Thrift Investment Board, HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Science Foundation (NSF), SENATE, White House Office
2014 · second_quarter · Health Issues
H.R. 4260, Ryan White Patient Equity and Choice Act
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Democratic |
| TX |
| Gregory W. Meeks | Democratic | NY |
| James P. Moran | Democratic | VA |
| Yvette D. Clarke | Democratic | NY |
Client expense: $1,020,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)